Skip to content

Investigating the effective dose of dexmedetomidine in preventing cough during extubation

Investigating the preventive effect of two different doses of dexmedetomidine on the incidence of cough and respiratory complications during extubation compared to the control group.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090129001615N8
Enrollment
105
Registered
2023-05-13
Start date
2023-05-22
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory complications during extubation.

Interventions

Intervention 1: Intervention group 1: 0.5 µg/kg of dexmedetomidine is injected as a bolus and then 0.3 µg/kg of dexmedetomidine is injected as an infusion, ten minutes before the endotracheal tube is

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years ASA1,2 need general anesthesia with tracheal intubation

Exclusion criteria

Exclusion criteria: Patients with heart failure Patients with respiratory failure Patients with renal failure Patients with hepatic failure Previous known allergy to study drugs heart block Uncontrolled blood pressure smokers Addiction to any type of addictive substance

Design outcomes

Primary

MeasureTime frame
Frequency of coughing during extubation. Timepoint: From the time of full awakening to 5 minutes after extubation. Method of measurement: Using direct observation, the occurrence or non-occurrence of cough is recorded.;Severity of cough. Timepoint: From the time of full awakening to 5 minutes after extubation. Method of measurement: Minogue scale.

Secondary

MeasureTime frame
Determination and comparison of respiratory rate in three groups. Timepoint: 5 minutes before the end of surgery, at the end of surgery, at the time of awakening, at the time of extubation, 2 minutes and 5 minutes after extubation, at the time of entering recovery and 10 minutes after recovery. Method of measurement: observation.;Determining and comparing the average dose of lidocaine and fentanyl used to control cough. Timepoint: From the time of full awakening to 5 minutes after extubation. Method of measurement: observation.;Determining and comparing the average dose of labetalol used in three groups. Timepoint: From the time of full awakening to 5 minutes after extubation. Method of measurement: observation.;Determining and comparing the average duration of surgery and anesthesia and stay in recovery in three groups. Timepoint: From the beginning of surgery to exit from recovery. Method of measurement: observation.;Determining and comparing the average dose of ondansetron consumed in three groups. Timepoint: From the time of full awakening to 5 minutes after extubation. Method of measurement: observation.;Determination and comparison of pain intensity in three groups. Timepoint: Every 15 minutes in recovery until leaving it. Method of measurement: Visual Analogue Scale.;Determining and comparing the frequency of nausea and vomiting in three groups. Timepoint: Every 15 minutes in recovery until leaving it. Method of measurement: observation.;Determining and comparing the average duration of extubation in three groups. Timepoint: At the time of extubation. Method of measurement: observation.;Determining and comparing the average level of consciousness in three groups. Timepoint: at 2 minutes and 5 minutes after extubation, at the time of entering recovery and 10 minutes after recovery. Method of measurement: Using a 4-point scale, 0=sleepy and unresponsive 1=sleepy but can be woken up 2=sleepy but opens eyes with voice command 3=fully alert.;Determination and comp

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzim Honarmand

Esfahan University of Medical Sciences

Honarmand@med.mui.ac.ir+98 31 3620 1992

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026